Results 81 to 90 of about 9,804 (228)

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice [PDF]

, 2015
Objective: Direct-acting antivirals (DAAs) inhibit hepatitis C virus (HCV) infection by targeting viral proteins that play essential roles in the replication process. However, selection of resistance-associated variants (RAVs) during DAA therapy has been
Ball, Jonathan K., Baumert, Thomas, Bhuju, Sabin, Brown, Richard J.P., Cortese, Riccardo, Doerrbecker, Juliane, Farhoudi, Ali, Geffers, Robert, Leroux-Roels, Geert, McClure, C. Patrick, Mesalam, Ahmed Atef, Meuleman, Philip, Nicosia, Alfredo, Pietschmann, Thomas, Troise, Fulvia, Van Den Eede, Naomi, Vercauteren, Koen, Verhoye, Lieven   +17 more
core   +4 more sources

Electrosynthesis of Bioactive Chemicals, From Ions to Pharmaceuticals

Advanced Functional Materials, Volume 36, Issue 16, 23 February 2026.
This review discusses recent advances in electrosynthesis for biomedical and pharmaceutical applications. It covers key electrochemical materials enabling precise delivery of ions and small molecules for cellular modulation and disease treatment, alongside catalytic systems for pharmaceutical synthesis.
Gwangbin Lee, Sojin Kim, Myeongeun Lee, Kyoungsuk Jin, Jimin Park   +4 more
wiley   +1 more source

Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program [PDF]

, 2016
Background and Aims: An HCV cure is now possible in a large proportion of HIV-HCV patient. We present real life results of a compassionate use program promoted by SIMIT (Infectious and Tropical Diseases Italian Society) of Dasabuvir and Ombitasvir ...
Andreoni, M., Angarano, G., Antinori, A., Boffa, N., Bruno, R., Cacopardo, B., Castelli, F., Cattelan, A., Chirianni, A., De Luca, A., Di Biagio, A., Di Perri, G., D’Arminio Monforte, A., Galli, M., Gentilotti, E., Giacometti, A., Gori, A., Lazzarin, A., Maggiolo, F., Mastroianni, C. M., Mussini, C., Parruti, G., Pasquazzi, C., Pennica, A., Puoti, M., Ricciardi, A., Rizzardini, G., Sarmati, L., Sighinolgi, L., Taliani, G., Teti, E., Vullo, V.   +31 more
core   +1 more source

Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use [PDF]

Journal of Hepatology, 2016
Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease and hepatocellular carcinoma. There have been rapid advances in HCV treatment with the development of oral direct-acting antivirals (DAAs). Studies have shown sustained virological response rates above 90% with combinations of DAAs, including patients with compensated ...
Dyson JK, Hutchinson J, Harrison L, Rotimi O, Tiniakos D, Foster GR, Aldersley MA, McPherson S   +7 more
openaire   +3 more sources

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters

The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug candidate for the treatment of chronic hepatitis C virus infection. Potential drug–drug interactions (DDIs) of bemnifosbuvir as a substrate or perpetrator with regard to ATP‐binding cassette (ABC) and solute carrier (SLC) transporters were evaluated in vitro and in clinical studies ...
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Nancy Agrawal, Janet Hammond   +9 more
wiley   +1 more source

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

ClinicoEconomics and Outcomes Research, 2017
Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg ...
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J   +8 more
doaj  

New hepatitis C therapies in clinical development

European Journal of Medical Research, 2011
With the current standard of care for the treatment of chronic hepatitis C, a combination of pegylated interferon alfa and ribavirin, sustained virologic response rates can be achieved in approximately 50% of patients only.
Vermehren Johannes, Sarrazin Christoph
doaj   +1 more source

Stability of the resistance to the thiosemicarbazone derived from 5,6-dimethoxy-1-indanone, a non-nucleoside polymerase inhibitor of bovine viral diarrhea virus. [PDF]

PLoS ONE, 2014
Bovine viral diarrhea virus (BVDV) is the prototype Pestivirus. BVDV infection is distributed worldwide and causes serious problems for the livestock industry.
Eliana F Castro, Rodolfo H Campos, Lucía V Cavallaro   +2 more
doaj   +1 more source

Ubiquitination dynamics in human tumour viruses: Viral infection, oncogenesis and antiviral therapy

The FEBS Journal, Volume 293, Issue 2, Page 325-347, January 2026.
The ubiquitin system is essential for cellular homeostasis and regulates many processes. Viruses, including oncogenic ones, exploit or evade this system to survive and replicate. This review explores how human tumour viruses manipulate the ubiquitination system to complete their life cycle, evade immunity and promote cancer.
Oscar Trejo‐Cerro, Martina Bergant Marušič, Justyna Broniarczyk   +2 more
wiley   +1 more source

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis [PDF]

, 2015
Importance Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis.
Cooper, James, Dore, Gregory J., Everson, Gregory, Freilich, Bradley, Ghesquiere, Wayne, Herring, Robert, Hughes, Eric A., Hézode, Christophe, Kwo, Paul, Lalezari, Jacob, McPhee, Fiona, Muir, Andrew J., Pockros, Paul J., Poordad, Fred, Ramji, Alnoor, Reau, Nancy, Sheikh, Aasim, Stuart, Katherine, Swenson, E. Scott, Thompson, Alexander J., Tran, Albert, Vierling, John, Yang, Rong, Yin, Philip D., Yozviak, Joseph   +24 more
core   +1 more source